Hoyte: Results from the study showed adults and children aged 13 years and older with uncontrolled asthma using the ProAir Digihaler and its integrated system had an 85.3% probability of higher ...

Had Teva not challenged Amneal on the basis of its five ProAir HFA patents, Amneal argues that the FDA could have approved its generic asthma med as early as April 2024, according to the FTC.

In October 2023, Teva Pharmaceuticals filed a patent infringement lawsuit against Amneal Pharmaceuticals alleging that their generic version of Teva’s ProAir® HFA inhaler infringed upon the ...

The report said that U.S. District Judge Stanley Chesler agreed with Amneal and the FTC, that Teva's patents only covered inhaler device technology, ordering it to remove the listings from the FDA ...

R&D, Inc. v. Amneal Pharms. of N.Y., LLC, affirming a lower court decision that Teva must delist five patents from the US Food and Drug Administration (FDA) Orange Book that claim inhalers for ...